Ronald V. Swanson
Ronald V. Swanson has a total of 261 co-authors. Here are the top co-authors by number of shared publications:
Melvin I. Simon
10 shared publications- Alena Zalutskaya
Blueprint Medicines Corporation, Cambridge, Massachusetts
7 shared publications - Christine Lihou
Tyra Biosciences, Carlsbad, California
7 shared publications - Cédric Pobel
Département d'Innovation Thérapeutique et Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Inserm U981, Gustave Roussy, Villejuif, France; Université Paris-Saclay, Gustave Roussy, Villejuif, France; Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
7 shared publications - Eric L. Allen
Tyra Biosciences, Carlsbad, California
7 shared publications - Erik Goluboff
Tyra Biosciences, Carlsbad, California
7 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Supplementary Data file describes the structure and synthesis method for dabogratinib.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::TACC3 fusion. CT images of a target lesion in the liver (A) and nontarget lesions in the liver (B) are shown at baseline and at 15.4 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3S249C mutation. CT images of a target lesion in the lung are shown at baseline and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates early clinical activity in a patient with mUC with an FGFR3::JAKMIP1 fusion. CT images of target lesions in the lung are shown at baseline, first partial response at 8 weeks, and at 15.7 weeks as a confirmatory PR.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Dabogratinib demonstrates in vitro and in vivo efficacy in FGFR3-driven bladder cancer models. A, Assessment of downstream signaling after treatment for 2 hours with dabogratinib at the indicated dose or vehicle control in the indicated FGFR3-driven bladder cancer cell lines. One representative biological replicate is shown on the left and quantification of the ratio of pERK to tERK of n = 3 biological replicates is shown on the right. B and C, Antitumor activity in the FGFR3S249C-activating mutant UM-UC-14 bladder cancer xenograft model in nu/nu mice of various dosages of dabogratinib: (B) 3, 6, and 9 mg/kg twice daily and (C) 6, 12, and 18 mg/kg once daily and erdafitinib (12.5 mg/kg twice daily) shown in both B and C. D and E, Body weight averages for the dosage groups depicted in B and C, respectively. All dosages were by oral administration. Data in B–E were derived from the same study but split into separate graphs to enable visualization of each group. Data from vehicle- and erdafitinib-treated groups were repeated in B and C, as well as in D and E. Data points represent mean tumor volume (n = 6 per group, except 6 mg/kg twice daily dabogratinib dosing group in which one animal was found dead at day 7 of treatment, with n = 5) and error bars represent SEM.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (3) , 408-415
Open AccessDabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity
Despite recent advances in the treatment of fibroblast growth factor receptor 3 (FGFR3)–altered metastatic urothelial carcinoma, there is no approved precision therapy that selectively targets FGFR3 while sparing other FGFR isoforms. Dabogratinib (TYRA-300)—a rationally designed selective FGFR3 inhibitor—was evaluated in vitro and in vivo. We also report three patient cases from the ongoing first-in-human, phase I/II SURF301 study (NCT05544552). Dabogratinib elicited a dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3S249C-activating mutation, dabogratinib treatment resulted in dose-dependent tumor growth inhibition with tumor regression observed at the highest doses. These preclinical findings are supported by the three case reports from the SURF301 study, which demonstrate early clinical activity in patients with advanced metastatic urothelial carcinoma with an FGFR3 fusion or activating mutation.
- Open Access
- 1 August 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (33) , 22704-22714
Targeting the Ion Channel Kv1.3 with Scorpion Venom Peptides Engineered for Potency, Selectivity, and Half-life
- 1 August 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (33) , 22704-22714
Open AccessTargeting the Ion Channel Kv1.3 with Scorpion Venom Peptides Engineered for Potency, Selectivity, and Half-life
- 12 February 2013
- Published by Wiley
- p. 123-142
Peptide‐Fc Fusion Therapeutics: Applications and Challenges
- 12 February 2013
- Published by Wiley
- p. 123-142
Peptide‐Fc Fusion Therapeutics: Applications and Challenges
- 28 February 2012
- Published by Wiley in Journal of Molecular Recognition
- Vol. 25 (3) , 125-135
Characterization of a high‐affinity human antibody with a disulfide bridge in the third complementarity‐determining region of the heavy chain
Disulfide bridges are common in the antigen‐binding site from sharks (new antigen receptor) and camels (single variable heavy‐chain domain, VHH), in which they confer both structural diversity and domain stability. In human antibodies, cysteine residues in the third complementarity‐determining region of the heavy chain (CDR‐H3) are rare but naturally encoded in the IGHD germline genes. Here, by panning a phage display library designed based on human germline genes and synthetic CDR‐H3 regions against a human cytokine, we identified an antibody (M3) containing two cysteine residues in the CDR‐H3. It binds the cytokine with high affinity (0.4 nm), recognizes a unique epitope on the antigen, and has a distinct neutralization profile as compared with all other antibodies selected from the library. The two cysteine residues form a disulfide bridge as determined by mass spectrometric peptide mapping. Replacing the cysteines with alanines did not change the solubility and stability of the monoclonal antibody, but binding to the antigen was significantly impaired. Three‐dimensional modeling and dynamic simulations were employed to explore how the disulfide bridge influences the conformation of CDR‐H3 and binding to the antigen. On the basis of these results, we envision that designing human combinatorial antibody libraries to contain intra‐CDR or inter‐CDR disulfide bridges could lead to identification of human antibodies with unique binding profiles. Copyright © 2012 John Wiley & Sons, Ltd.
- 28 February 2012
- Published by Wiley in Journal of Molecular Recognition
- Vol. 25 (3) , 125-135
Characterization of a high‐affinity human antibody with a disulfide bridge in the third complementarity‐determining region of the heavy chain
Disulfide bridges are common in the antigen‐binding site from sharks (new antigen receptor) and camels (single variable heavy‐chain domain, VHH), in which they confer both structural diversity and domain stability. In human antibodies, cysteine residues in the third complementarity‐determining region of the heavy chain (CDR‐H3) are rare but naturally encoded in the IGHD germline genes. Here, by panning a phage display library designed based on human germline genes and synthetic CDR‐H3 regions against a human cytokine, we identified an antibody (M3) containing two cysteine residues in the CDR‐H3. It binds the cytokine with high affinity (0.4 nm), recognizes a unique epitope on the antigen, and has a distinct neutralization profile as compared with all other antibodies selected from the library. The two cysteine residues form a disulfide bridge as determined by mass spectrometric peptide mapping. Replacing the cysteines with alanines did not change the solubility and stability of the monoclonal antibody, but binding to the antigen was significantly impaired. Three‐dimensional modeling and dynamic simulations were employed to explore how the disulfide bridge influences the conformation of CDR‐H3 and binding to the antigen. On the basis of these results, we envision that designing human combinatorial antibody libraries to contain intra‐CDR or inter‐CDR disulfide bridges could lead to identification of human antibodies with unique binding profiles. Copyright © 2012 John Wiley & Sons, Ltd.